Table of Contents

---

---

SECURITIES AND EXCHANGE COMMISSION

---

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 14, 2003

La Jolla Pharmaceutical Company

N/A

---

---

---

 

---

	Item 5. Other Events and Required FD Disclosure.
	Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
SIGNATURES
EXHIBIT INDEX
EXHIBIT 99.1
EXHIBIT 99.2

---

Table of Contents

Item 5. Other Events and Required FD Disclosure.

                   On November 14, 2003, La Jolla Pharmaceutical Company (the “Company”) issued a press release announcing that it had been selected to be added to the NASDAQ Biotechnology Index effective November 24, 2003. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

                   On November 17, 2003, the Company issued a press release announcing that Matthew Linnik, Ph.D., the Company’s Chief Scientific Officer and Executive Vice President of Research, and two of the Company’s principal investigators, presented analyses showing associations between changes in levels of antibodies to double-stranded DNA and the relative risk of renal flare in the Company’s Phase 2/3 and Phase 3 trials of Riquent(TM) at the American Society of Nephrology Annual Meeting. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

              (c) Exhibits. The following exhibits are filed with this report on Form 8-K:

 

---

Table of Contents

SIGNATURES

                   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

---

Table of Contents

EXHIBIT INDEX